2Cai W,Xie Q,An B,et al.On-treatment serum HBsAg level is predictive of sustained off-treatment virologic response to telbivudine in HBeAg-positive chronic hepatitis B patients[J].J Clin Virol,2010,48(1):22-26.
4Alexopoulou A,Dourakis SP,Pandelidaki H,et al.Detection of a hepatitis B surface antigen variant emerging in a patient with chronic lymphocytic leukaemia treated with fludarabine[J].J Med Virol,2006,78(8):1043-1046.
5Kurashige N,Hiramatsu N,Ohkawa K,et al.Factors contributing to antiviral effect of aclefovir dipivoxil therapy added to ongoing lamivudine treatment in patients withlamivudine-resistantchronichepatitisB[J].JGastroenterol,2009,44(6):601-607.
7Miura Y,Shibuya A,Adachi S,et al.Occult hepatitis B virus infection as a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C in whom viral eradication fails[J].Hepatol Res,2008,38(6):546-556.
8Hsu HM, Lu CF, Lee SC, et al. Seroepidemiology surey for hepatitis B virus infection in Taiwan: the effect of hepatitis B mass immuination. J Infect Dis, 1999,179:367-370.
9WHO.Hepatitis B surface antigen assay: operational characteristics.2000.1-15.
10Norihiro F,Jun H,Yasunori S.The elimination Of hepatitis B virus infection:changing seroepidemiology of hepatitis A and B virus infection in Okinawa Japan over a 26-year period Am J Med Hyp,1998.59:693—698.
